Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines

Journal of Psychopharmacology

Volumn 14, Issue 1, 2000, Pages 3-20

  Anderson, I M ^a   Nutt, D J ^b   Deakin, J F W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antidepressants; Depressive disorder; Evidence based guidelines; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NOMIFENSINE; NORTRIPTYLINE; PHENELZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; BLOOD DYSCRASIA; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; INSOMNIA; META ANALYSIS; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRESCRIPTION; PRIAPISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SOMNOLENCE; TREATMENT FAILURE;

EID: 0034059513     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110001400101     Document Type: Review

References (209)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th edn. American Psychiatric Association, Washington, DC
2. Anderson I M (1997) Lessons to be learnt from meta-analyses of newer versus older antidepressants. Adv Psychiatr Treat 3: 58-63
3. Anderson I M (1998) SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl. 1): 11-17
4. Anderson I M (1999) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Dis (in press)
5. Andrews G, Slade T, Peters L (1999) Classification in psychiatry: ICD-10 versus DSM-IV. BrJ Psychiatry 174: 3-5
6. Angst J (1997) A regular review of the long term follow up of depression. BMJ 315: 1143-1146
7. Angst J, Scheidegger P, Stabl M (1993) Efficacy of moclobemide in different patient groups: results of new subscales of the Hamilton Depression Rating Scale. Clin Neuropharmacol 16 (Suppl. 2): S55-S62
8. Aronson R, Offman H J, Joffe R T, Naylor C D (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53: 842-848
9. Austin M-P V, Souza F G M, Goodwin G M (1991) Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Br J Psychiatry 159: 510-514
10. Baldwin D S, Thomas C S, Birtwistle J (1997) Effects of antidepressant drugs on sexual function. Int J Psychiatr Clin Pract 1: 47-58
11. Barrett J E, Barrett J A, Oxman T E, Gerber P D (1988) The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 45: 1100-1106
12. Beasley C M, Dornseif B E, Bosomworth J C, Sayler M E, Rampey A H, Heiligenstein J H, Thompson V L, Murphy D J, Masica D N (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 303: 685-692
13. Bebbington P, Dunn G, Jenkins R, Lewis G, Brugha T, Farrell M, Meltzer H (1998) The influence of age and sex on the prevalence of depressive conditions: report from the the National Survey of Psychiatric Morbidity. Psychol Med 28: 9-19
14. Belsher G, Costello C G (1988) Relapse after recovery from unipolar depression: a critical review. Psychol Bull 104:84-96
15. Bielski R J, Friedel R O (1976) Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry 33: 1479-1489
16. Black D W, Bell S, Hulbert J, Nasrallah A (1988) The importance of Axis II in patients with major depression. J Affect Dis 14: 115-122
17. Blacker C V, Clare A W (1988) The prevalence and treatment of depression in general practice. Psychopharmacology 95: S14-S17
18. Blashki T G, Mowbray R, Davies B (1971) Controlled trial of amitriptyline in general practice. BMJ 1: 133-138
19. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (1999) Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 174: 297-303
20. Boot D, Gillies P, Fenelon J, Reubin R, Wilkins M, Gray P (1994) Evaluation of the short-term impact of counseling in general practice. Pat Ed Counsell 24: 79-89
21. British National Formulary (1999) Number 37. British Medical Association and Royal Pharmaceutical Society of Great Britain. The Pharmaceutical Press, London
22. Brown G W, Harris T O, Hepworth C (1994) Life events and endogenous depression: a puzzle re-examined. Arch Gen Psychiatry 51: 525-534
23. Brown W A, Johnson M F, Chen M G (1992) Clinical features of depressed patients who do and do not improve with placebo. Psychiatr Res 41: 203-214
24. Brugha T S, Bebbington P E, MacCarthy B, Sturt E, Wykes T (1992) Antidepressants may not assist recovery in practice: a naturalistic prospective study. Acta Psychiatr Scand 86: 5-11
25. Bryant S G, Fisher S, Kluge R M (1987) Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system. J Clin Psychopharmacol 7: 78-82
26. Burns, D (1983) Feeling good. Signet Press
27. Chan C H, Janicak P G. Davis J M, Altman E, Andriukaitis S, Hedeker D (1987) Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 48: 197-200
28. Cole M G, Bellavance F, Mansour A (1999) Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry 156: 1182-1189
29. Conti L, Dell'Osso L (1989) Clinical predictors of response to fluvoxamine, imipramine and placebo. New Trends Exp Clin Psychiatry 5: 221-229
30. Coryell W, Endicott J, Winokur G (1992) Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. Am J Psychiatry 149: 100-107
31. Coulehan J L, Schulberg H C, Block M R, Madonia M J, Rodriguez E (1997) Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Int Med 157: 1113-1120
32. Cramer J A, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49: 196-201
33. Cuijpers P (1997) Bibliotherapy in unipolar depression: a meta-analysis. J Behav Ther Exp Psychiatry 28: 139-147
34. Davidson J R T, Meltzer-Brody S E (1999) The underrecognition and undertreatment or depression: what is the breadth and depth of the problem? J Clin Psychiatry 60 (Suppl. 7): 4-9
35. Davis R, Whittington R, Bryson H M (1997) Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53: 608-636
36. Dawson R, Lavori P W, Coryell W H, Endicott J, Keller M B (1998) Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. J Affect Dis 49: 31-44
37. den Boer J A, Westenberg H G (1988) Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59-74
38. DeRubeis R J, Gelfand L A, Tang T Z, Simons A D (1999) Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156: 1007-1013
39. Depression Guideline Panel (1993a) Clinical practice guideline number 5. Depression in primary care, vol. 1. Detection and diagnosis. US Department of Health and Human Services. Agency for Health Care Policy and Research, Rockville, MD
40. Depression Guideline Panel (1993b) Clinical practice guideline number 5. Depression in primary care, vol. 2. Treatment of major depression. US Department of Health and Human Services. Agency for Health Care Policy and Research, Rockville, MD
41. Dilsaver S C, Greden J F, Snider R M (1987) Antidepressant withdrawal syndromes: phenomenology and physiopathology. Int Clin Psychopharmacol 2: 1-19
42. Donoghue J (1998) Sub-optimal use of tricyclic antidepressants in primary care. Acta Psychiatr Scand 98: 429-431
43. Dowrick C, Buchan I (1995) Twelve month outcome of depression in general practice: does detection or disclosure make a difference? BMJ 311: 1274-1276
44. Duggan C F, Lee A S, Murray R M (1991) Do different subtypes of hospitalized depressives have different long-term outcomes? Arch Gen Psychiatry 48: 308-312
45. Dunn R L, Donoghue J M, Ozminkowski R J, Stephenson D, Hylan T R (1999) Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 13: 136-143
46. Einarson T R, Arikian S R, Casciano J, Doyle J J (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296-308
47. Emmanuel J, Simmonds S, Tyrer P (1998) Systematic review of the outcome of anxiety and depressive disorders. Br J Psychiatry 173 (Suppl. 34): 35-41
48. Emrich H M, Berger M, Riemann D, von Zerssen D (1987) Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry 20: 60-63
49. Entsuah R, Rudolph, R L (1999) A comparative pooled analysis of the effect of venlafaxine and selective serotonin reuptake inhibitors on remission in patients with major depression. Poster presented at the American Psychiatric Association, Washington DC
50. Ernst E, Rand J I, Stevinson C (1998) Complementary therapies for depression: an overview. Arch Gen Psychiatry 55: 1026-1032
51. Ezquiaga E, Garcia A, Bravo F, Pallares T (1998) Factors associated with outcome in major depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol 33: 552-557
52. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A (1986) Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 143: 888-891
53. Fava G A, Grandi S, Zielezny M, Canestrari R, Morphy M A (1994a) Cognitive behavioural treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 151: 1296-1299
54. Fava M, Rosenbaum J F, McGrath P J, Stewart J W, Amsterdam J D, Quitkin F M (1994b) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372-1374
55. Fava M, Uebelacker L A, Alpert J E, Nierenberg A A, Pava J A, Rosenbaum J F (1997) Major depressive subtypes and treatment response. Biol Psychiatry 42: 568-576
56. Feighner J P (1994) The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 55 (Suppl. A): 62-68
57. Fitton A, Faulds D, Goa K L (1992) Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561-596
58. Flint A J, Rifat S L (1999) Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 156: 943-945
59. Frances A J, Kahn D A, Carpenter D, Docherty J P, Donovan S L (1998) The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 59 (Suppl. 4): 73-79
60. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R (1998) Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 59: 229-232
61. Frank E, Kupfer D J, Perel J M, Cornes C, Jarrett D B, Mallinger A G, Thase M E, McEachran A B, Grochocinski V J (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093-1099
62. Frank E, Kupfer D J, Perel J M, Cornes C, Mallinger A G, Thase M E, McEachran A B, Grochocinski V J (1993) Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Dis 27: 139-145
63. Frank E, Prien R F, Jarrett R B, Keller M B, Kupfer D J, Lavori P W, Rush A J, Weissman M M (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855
64. Freeling P, Rao B M, Paykel E S, Sireling L I, Burton R H (1985) Unrecognised depression in general practice. BMJ 290: 1880-1883
65. Friedli K, King M B, Lloyd M, Horder J (1997) Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care. Lancet 350: 1662-1665
66. Friedman R A, Markowitz J C, Parides M, Gniwesch L, Kocsis J H (1999) Six months of desipramine for dysthymia: can dysthymic patients achieve normal social functioning? J Affect Dis 54: 283-286
67. Geddes J R, Freemantle N, Mason J, Eccles M P, Boynton J (1999) SSRIs versus alternative antidepressants in depressive disorder (Cochrane Review). In: The Cochrane Library, issue 4. Update Software, Oxford
68. Georgotas A, McCue R E, Cooper T B, Nagachandran N, Friedhoff A (1989) Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatr Res 28: 1-9
69. Gill D, Hatcher S A (1999) A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness (Cochrane Review). In: The Cochrane Library, issue 4. Update Software, Oxford
70. Glick I D, Burti L, Suzuki K, Sacks M (1991) Effectiveness in psychiatric care. I A cross-national study of the process of treatment and outcomes of major depressive disorder. J Nerv Ment Dis 179: 55-63
71. Gloaguen V, Cottraux J, Cucherat M, Blackburn I M (1998) A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Dis 49: 59-72
72. Goethe J W, Szarek B L, Cook W H (1988) A comparison of adequately vs. inadequately treated depressed patients. J Nerv Ment Dis 176: 465-470
73. Goldberg D, Bridges K, Grayson D (1988) Detecting anxiety and depression in general medical settings. BMJ 297: 897-899
74. Gormley N, O'Leary D, Costello F (1999) First admissions for depression: is the 'no-treatment' interval a critical predictor of time to remission? J Affect Dis 54: 49-54
75. Greden J F (1993) Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 54 (Suppl. 8): 39-45
76. Grimshaw J M, Russell I T (1993) Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 342: 1317-1322
77. Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, Tomenson B, Creed F (1999) Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch Gen Psychiatry (in press)
78. Haddad P M (1998) The SSRI discontinuation syndrome. J Psychopharmacol 12: 305-313
79. Haddad P (1999) Do antidepressants have any potential to cause addiction? J Psychopharmacol 13: 300-307
80. Hammerlein A, Derendorf H, Lowenthal D T (1998) Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Pharmacokinetics 35: 49-64
81. Harvey I, Nelson S J, Lyons R A, Unwin C, Monaghan S, Peters T J (1998) A randomized controlled trial and economic evaluation of counselling in primary care. BrJ Gen Pract 48: 1043-1048
82. Henry J A, Alexander C A, Sener E K (1995) Relative mortality from overdose of antidepressants. BMJ 310: 221-224
83. Holden J M, Sagovsky R, Cox J L (1989) Counselling in a general practice setting: controlled study of health visitor intervention in treatment of postnatal depression. BMJ 298: 223-226
84. Hotopf M, Hardy R, Lewis G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170: 120-127
85. Isacsson G, Boethius G, Bergman U (1992) Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 85: 444-448
86. Isacsson G, Boethius G, Henriksson S, Jones J K, Bergman U (1999) Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Dis 53: 15-22
87. Isometsa E T, Henriksson M M, Aro H M, Heikkinen M E, Kuoppasalmi K I, Lonnqvist J K (1994) Suicide in major depression. Am J Psychiatry 151: 530-536
88. Jenkins R, Lewis G, Bebbington P, Brugha T, Farrell M, Gill B, Meltzer H (1997) The National Psychiatric Morbidity Surveys of Great Britain - initial findings from the household surveys. Psychol Med 27: 775-789
89. Judd L L (1997) The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 54: 989-991
90. Judd L L, Akiskal H S, Maser J D, Zeller P J, Endicott J, Coryell W, Paulus M P, Kunovac J L, Leon A C, Mueller T I, Rice J A, Keller M B (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55: 694-700
91. Katon W, Von Korff M, Lin E, Walker E, Simon G E, Bush T, Robinson P, Russo J (1995) Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 273: 1026-1031
92. Katon W, Robinson P, Von Korff M, Lin E, Bush T, Ludman E, Simon G, Walker E (1996) A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 53: 924-932
93. Katz M M, Koslow S H, Maas J W, Frazer A, Bowden C L, Casper R, Croughan J, Kocsis J, Redmond E J (1987) The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 17: 297-309
94. Keller M B (1994) Course, outcome and impact on the community. Acta Psychiatr Scand 89 (Suppl. 383): 24-34
95. Keller M B, Lavori P W, Mueller T I, Endicott J, Coryell W, Hirschfeld R M, Shea T (1992) Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49: 809-816
96. Kessler R C, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S, Wittchen H U, Kendler K S (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19
97. Khan A, Cohen S, Dager S, Avery D H, Dunner D L (1989) Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Dis 17: 33-38
98. Kocsis J H, Croughan J L, Katz M M, Butler T P, Secunda S, Bowden C L, Davis J M (1990) Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 147: 621-624
99. Koran L M, Hamilton S H, Hertzman M, Meyers B S, Halaris A E, Tollefson G D, Downs J M, Folks D G, Jeste D V, Lazarus L W, Satlin A (1995) Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 15: 421-427
100. Kupfer D J (1991) Long-term treatment of depression. J Clin Psychiatry 52 (Suppl. 5): 28-34
101. Lancaster S G, Gonzalez J P (1989) Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 37: 123-140
102. Lejoyeux M, Adès J (1997) Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 58 (Suppl. 7): 11-16
103. Lima M S, Moncrieff J (1999) Drugs versus placebo for dysthymia (Cochrane Review). In: The Cochrane Library, issue 4. Update Software, Oxford
104. Lin E H, Simon G E, Katon W J, Russo J E, Von Korff M, Bush T M, Ludman E J, Walker E A (1999) Can enhanced acute-phase treatment of depression improve long-term outcomes? A report of randomized trials in primary care. Am J Psychiatry 156: 643-645
105. Lin E H B, Katon W J, Simon G E, Von K M, Bush T M, Rutter C M, Saunders K W, Walker E A (1997) Achieving guidelines for the treatment of depression in primary care: is physician education enough? Med Care 35: 831-842
106. Lin E H B, Katon W J, VonKorff M, Russo J E, Simon G E, Bush T M, Rutter C M, Walker E A, Ludman E (1998) Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 7: 443-449
107. Linde K, Mulrow C D (1999) St John's wort for depression (Cochrane Review). In: The Cochrane Library, issue 4. Update software, Oxford
108. Lloyd C, Zisook S, Click M, Jaffe K E (1981) Life events and response to antidepressants. J Hum Stress 7: 2-15
109. Lloyd K R, Jenkins R, Mann A (1996) Long term outcome of patients with neurotic illness in general practice. BMJ 313: 26-28
110. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O (1994) Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Dis 32: 169-177
111. Loonen A J, Peer P G, Zwanikken G J (1991) Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharm Week Sci 13: 167-175
112. Malt U F, Robak O H, Madsbu H -P, Bakke O, Loeb M (1999) The Norwegian naturalistic treatment study of depression in general practice (NORDEP) - I: randomised double blind study. BMJ 318: 1180-1184
113. Markowitz J C (1994) Psychotherapy of dysthymia. Am J Psychiatry 151: 1114-1121
114. Martin R M, Hilton S R, Kerry S M, Chards N M (1997) General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ 314: 646-651
115. Mason J, Freemantle N, Young N (1999) The effect of the distribution of Effective Health Care Bulletins on prescribing selective serotonin reuptake inhibitors in primary care. Health Trends 30: 120-122
116. McGrath P J, Stewart J W, Nunes E V, Ocepek-Welikson K, Rabkin J G, Quikin F M, Klein D F (1993) A double-blind crossover trial of imipramine and phenelzine for out patients with treatment-refractory depression. Am J Psychiatry 150: 118-123
117. Mittmann N, Herrmann N, Einarson T R, Busto U E, Lanctot L L, Liu B A, Shulman K I, Silver I L, Naranjo C A, Shear N H (1998) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Dis 46: 191-217
118. Montgomery S A (1994) Long-term treatment of depression. Br J Psychiatry 165 (Suppl. 26): 31-36
119. Montgomery S A, Cowen P J, Deakin W, Freeling P, Hallstrom C, Katona C, King D, Leonard B, Levine S, Phanjoo A, Peet M, Thompson C (1993a) Guidelines for treating depressive illness with antidepressants. A statement from the British Association for Psychopharmacology. J Psychopharmacol 7: 19-23
120. Montgomery S A, Rasmussen J G, Tanghoj P (1993b) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8: 181-188
121. Montgomery S A, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53
122. Murphy F C, Sahakian B J, O'Carroll R E (1998) Cognitive impairment in depression: psychological models and clinical issues. In Ebert D, Ebmeier K P (eds), New models of depression. Advances in biological psychiatry. Karger, Basel, pp. 1-33
123. Murray C J L, Lopez A D (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349: 1436-1442
124. Mynors-Wallis L, Gath D (1997) Predictors of treatment outcome for major depression in primary care. Psychol Med 27: 731-736
125. Mynors-Wallis L M, Gath D H, Lloyd-Thomas A R, Tomlinson D (1995) Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 310: 441-445
126. Nelson J C, Mazure C M, Jatlow P I (1990) Does melancholia predict response in major depression? J Affect Dis 18: 157-165
127. Nobler M S, Sackeim H A (1994) Refractory depression and electroconvulsive therapy. In Nolen W A, Zohar J, Roose S P, Amsterdam J (eds), Refractory depression: current strategies and future directions. John Wiley & Sons Ltd, Chichester, pp. 69-81
128. Nolen W A, Van de Putte J J, Digken W A, Kamp J S, Blansjaar H J, Kramer H J, Haffmans J (1988a) Treatment strategy in depression. I Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial cross-over study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 78: 668-675
129. Nolen W A, Van de Putte J J, Dijken W A, Kamp J S, Blansjaar B A, Kramer H J, Haffmans J (1988b) Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 78: 676-683
130. Old Age Depression Interest Group (1993) How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. BrJ Psychiatry 162: 175-182
131. Olfson M, Klerman G L (1993) Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 150: 571-577
132. Ottevanger E A (1991) The efficacy of fluvoxamine in patients with severe depression. Br J Clin Res 2: 125-132
133. Pagliaro L A, Pagliaro A M (1995) Abuse potential of antidepressants: does it exist? CNS Drugs 4: 247-252
134. Pande A C, Birkett M, Fechner-Bates S, Haskett R F, Greden J F (1996) Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 40: 1017-1020
135. Partonen T, Lonnqvist J (1996) Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Dis 41: 93-99
136. Paykel E S (1978) Contribution of life events to causation of psychiatric illness. Psychol Med 8: 245-253
137. Paykel E S, Hollyman J A, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Dis 14: 83-95
138. Paykel E S, Hart D, Priest R G (1998) Changes in public attitudes to depression during the Defeat Depression Campaign. Br J Psychiatry 173: 519-522
139. Peet M (1994) Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164: 549-550
140. Persons J B, Thase M E, Crits C P (1996) The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry 53: 283-290
141. Peveler R, George C, Kinmonth A L, Campbell M, Thompson C (1999) Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 319: 612-615
142. Pharmacia & Upjohn Limited (1997) Edronax (reboxetine): summary of product characteristics
143. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995) Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 166: 424-443
144. Prien R F, Kupfer D J (1986) Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 143: 18-23
145. Priest R G, Vize C, Roberts A, Roberts M, Tylee A (1996) Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ 313: 858-859
146. Quitkin F M, Rabkin J G, Ross D, McGrath P J (1984) Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry 41: 238-245
147. Quitkin F M, Rabkin J G, Markowitz J M, Stewart J W, McGrath P J, Harrison W (1987) Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 44: 259-267
148. Quitkin F M, Harrison W, Stewart J W, McGrath P J, Tricamo E, Ocepek-Welikson K, Rabkin J G, Wager S G, Nunes E, Klein D F (1991a) Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 48: 319-323
149. Quitkin F M, Rabkin J G, Stewart J W, McGrath P J, Harrison W, Ross D C, Tricamo E, Fleiss J, Markowitz J, Klein D F (1991b) Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 148: 193-196
150. Quitkin F M, Stewart J W, McGrath P J, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin J G, Klein D F (1993) Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 150: 566-570
151. Quitkin F M, McGrath P J, Stewart J W, Ocepek-Welikson K, Taylor B P, Nunes E, Deliyannides D, Agosti V, Donovan S J, Petkova E, Klein D F (1996) Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 53: 785-792
152. Ramana R, Paykel E S, Surtees P G, Melzer D, Mehta M A (1999) Medication received by patients with depression following the acute episode: adequacy and relation to outcome. Br J Psychiatry 174: 128-134
153. Reimherr F W, Amsterdam J D, Quitkin F M, Rosenbaum J F, Fava M, Zajecka J, Beasley C M J, Michelson D, Roback P, Sundell K (1998) Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 155: 1247-1253
154. Revicki D A, Simon G E, Chan K, Katon W, Heiligenstein J (1998) Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 47: 446-452
155. Reynolds C F, Perel J M, Frank E, Cornes C, Miller M D, Houck P R, Mazumdar S, Stack J A, Pollock B G, Dew M A, Kupfer D J (1999) Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 156: 1177-1181
156. Robinson P, Katon W, Von Korff M, Bush T, Simon G, Lin E, Walker E (1997) The education of depressed primary care patients: what do patients think of interactive booklets and a video? J Fam Pract 44: 562-571
157. Rodney J, Prior N, Cooper B, Theodoros M, Browning J, Steinberg B, Evans L (1997) The comorbidity of anxiety and depression. Aust NZ J Psychiatry 31: 700-703
158. Ronalds C, Creed F, Stone K, Webb S, Tomenson B (1997) The outcome of anxiety and depressive disorders in general practice. Br J Psychiatry 171: 427-433
159. Rosenbaum J F, Fava M, Hoog S L, Ascroft R C, Krebs W B (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44: 77-87
160. Rosholm J U, Gram L F, Isacsson G, Hallas J, Bergman U (1997) Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 52: 205-209
161. Rost K, Zhang M, Fortney J, Smith J, Coyne J, Smith-GR J (1998) Persistently poor outcomes of undetected major depression in primary care. Gen Hosp Psychiatry 20: 12-20
162. Rush A J, Weissenburger J E (1994) Melancholic symptoms features and DSM-IV. Am J Psychiatry 151: 489-498
163. Rutz W, von Knorring L, Wålinder J (1992) Long-term effects of an educational program for general practitioners given by the Swedish Committee of the Prevention and Treatment of Depression. Acta Psychiatr Scand 85: 83-88
164. Salokangas R K R, Poutanen O, Stengård E, Jähi R, Palo-oja T (1996) Prevalence of depression among patients seen in community health centres and community mental health centres. Acta Psychiatr Scand 93: 427-433
165. Sato T, Sakado K, Sato S (1993) Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression? Acta Psychiatr Scand 88: 342-349
166. Schulberg H C, Block M R, Madonia M J, Scott C P, Rodriguez E, Imber S D, Perel J, Lave J, Houck P R, Coulehan J L (1996) Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 53: 913-919
167. Schulberg H C, Katon W, Simon G E, Rush A J (1998) Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 55: 1121-1127
168. Schulberg H C, Katon W J, Simon G E, Rush A J (1999) Best clinical practice: guidelines for managing major depression in primary medical care. J Clin Psychiatry 60 (Suppl. 7): 19-26
169. Schwenk T L, Coyne J C, Fechner B S (1996) Differences between detected and undetected patients in primary care and depressed psychiatric patients. Gen Hosp Psychiatry 78: 407-415
170. Scott C, Tacchi M J, Jones R, Scott J (1997) Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. Br J Psychiatry 171: 131-134
171. Scott J (1995) Psychological treatments for depression: an update. Br J Psychiatry 167: 289-292
172. Shea M T, Pilkonis P A, Beckham E, Collins J F, Elkin I, Sotsky S M, Docherty J P (1990) Personality disorder and treatment outcome in the NIMH Treatment of Depression Collaborative Research Programme. Am J Psychiatry 147: 711-718
173. Shekelle P G, Woolf S H, Eccles M, Grimshaw J (1999) Developing guidelines. BMJ 378: 593-596
174. Simon G E, Goldberg D, Tiemens B G, Ustun T B (1999a) Outcomes of recognized and unrecognized depression in an international primary care study. Gen Hosp Psychiatry 21: 97-105
175. Simon G E, Heiligenstein J H, Revicki D A, VonKorff M, Katon W, Ludman E, Grothaus L, Wagner E H (1999b) Long-term outcomes of initial antidepressant drug treatment choice in a 'real world' randomized trial. Arch Fam Med. 8: 319-325
176. Simon G E, Lin E H, Katon W, Saunders K, VonKorff M, Walker E, Bush T, Robinson P (1995) Outcomes of 'inadequate' antidepressant treatment. J Gen Int Med 10: 663-670
177. Sitsen J M A, Zivkov M (1995) Mirtazapine: clinical profile. CNS Drugs 4 (Suppl. 1): 39-48
178. Song F, Freemantle N, Sheldon T A, House A, Watson P, Long A, Mason J (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306: 683-687
179. Sotsky S M, Simmens S J (1999) Pharmacotherapy response and diagnostic validity in atypical depression. J Affect Disord 54: 237-247
180. Sotsky S M, Glass D R, Shea M T, Pilkonis P A, Collins J F, Elkin I, Watkins J T, Imber S D, Leber W R, Moyer J (1991) Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 148: 997-1008
181. Souza F G, Goodwin G M (1991) Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 158: 666-675
182. Stevens L, Kinmonth A L, Peveler R, Thompson C (1997) The Hampshire Depression Project: development and piloting of clinical practice guidelines and education about depression in primary health care. Med Educat 31: 375-379
183. Stewart J W, Quitkin F M, McGrath P J, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P (1998) Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 55: 334-343
184. Stratta P, Bolino F, Cupillari M, Casacchia M (1991) A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 6: 193-196
185. Surtees P G, Wainwright N W (1996) Fragile states of mind: neuroticism, vulnerability and the long-term outcome of depression. Br J Psychiatry 169: 338-347
186. Swinkels J A, de Jonghe F (1995) Safety of antidepressants. Int Clin Psychopharmacol 9 (Suppl 4): 19-25
187. Tamura, R, Michelson, D, Sundell, K, Beasley, C M (1998) Adverse event profiles associated with long-term fluoxetine treatment. Presented at the Annual Meeting of American Psychiatric Association 1998, Toronto, Ontario, Canada, 30 May to 4 June
188. Task Force on the Use of Laboratory Tests in Psychiatry (1985) Tricyclic antidepressants-blood level measurements and clinical outcome: an APA task force report. Am J Psychiatry 142: 155-162
189. Taylor, D, McConnell, D, McConnell, H, Abel, K, Kerwin, R (1999) The Bethlam & Maudsley NHS Trust prescribing guidelines, 5th edn. Martin Dunitz Ltd, London
190. Thase M E (1997) Psychotherapy of refractory depressions. Depress Anxiety 5: 190-201
191. Thase M E, Sullivan L R (1995) Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 4: 261-277
192. Thase M E, Friedman E S (1999) Is psychotherapy an effective treatment for melancholia and other severe depressive states? J Affect Dis 54: 1-19
193. Thase M E, Mallinger A G, McKnight D, Himmelhoch J M (1992) Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149: 195-198
194. Thase M E, Trivedi M H, Rush A J (1995) MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12: 185-219
195. Thase M E, Blomgren S L, Birkett M A, Apter J T, Tepner R G (1997a) Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58: 16-21
196. Thase M E, Greenhouse J B, Frank E, Reynolds C F, Pilkonis P A, Hurley K, Grochocinski V, Kupfer D J (1997b) Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 554: 1009-1015
197. Tiemens B G, Ormel J, Simon G E (1996) Occurrence, recognition, and outcome of psychological disorders in primary care. Am J Psychiatry 153: 636-644
198. Tiemens B G, VonKorff M, Lin E H B (1999) Diagnosis of depression by primary care physicians versus a structured diagnostic interview: understanding discordance. Gen Hosp Psychiatry 21: 87-96
199. Tomaszewska W, Peselow E D, Barouche F, Fieve R R (1996) Antecedent life events, social supports and response to antidepressants in depressed patients. Acta Psychiatr Scand 94: 352-357
200. Trivedi, M H, Pitts, C D, Oakes, R, Gergel, I P (1998) Safety of paroxetine in the long-term treatment of depression. Presented at the Annual Meeting of American Psychiatric Association 1998, Toronto, Ontario, Canada, 30 May to 4 June
201. Tylee A, Freeling P, Kerry S, Burns T (1995) How does the content of consultations affect the recognition by general practitioners of major depression in women? Br J Gen Pract 45: 575-578
202. Vallejo J, Gasto C, Catalan R, Bulbena A, Menchon J M (1991) Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators. J Affect Dis 21: 151-162
203. Weissman M M, Markowitz J C (1994) Interpersonal psychotherapy: current status. Arch Gen Psychiatry 51: 599-606
204. Weissman M M, Bland R C, Canino G J, Faravelli C, Greenwald S, Hwu H-G, Joyce P R, Karem E G, Lee C-K, Lellouch J, Lepine J P, Newman S C, Rubio-Stipec M, Wells J E, Wickramaratne P J, Wittchen H-U, Yeh E-K (1996) Cross-national epidemiology of major depression and bipolar disorder. JAMA 276: 293-299
205. Wells K B, Golding J M, Burnham M A (1988) Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 145: 976-981
206. Whooley M A, Avins A L, Miranda J, Browner W S (1997) Case-finding instruments for depression. Two questions are as good as many. J Gen Int Med 12: 439-445
207. Wilkinson M J, Barczak P (1988) Psychiatric screening in general practice: comparison of the general health questionnaire and the hospital anxiety depression scale. J Royal Coll Gen Pract 38: 311-313
208. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders-clinical descriptions and diagnostic guidelines. WHO, Geneva
209. Zigmond A S, Snaith R D (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67: 361-370